OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
INVA52

Invicta Diagnostic Ltd

Healthcare Facilities & ServicesVerified

The company's capital structure shows no dilution risk, with basic and diluted shares outstanding being equal at 12,571,973 shares. However, liquidity risk could not be assessed due to missing balance-sheet inputs and absence of going-concern language in source documents. No valuation snapshot data is available to evaluate profitability or returns relative to industry benchmarks. The company's revenue concentration and geographic exposure are not disclosed in available documents, preventing assessment of segment or regional risk. No financial history or outlook data is available to determine growth trajectory or revenue trends. Risk assessment indicates low dilution potential, but liquidity risk remains unassessed due to missing financial data. No recent filings or transcripts are available to identify material events or strategic developments.

30-day price · INVA+19.50 (+27.9%)
Low$66.20High$104.50Close$89.50As of17 May, 00:00 UTC
Profile
CompanyInvicta Diagnostic Ltd
TickerINVA.NS
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Invicta Diagnostic Ltd provides diagnostic services and related healthcare solutions.

Classification. The company is classified under the Healthcare economic sector, Healthcare Services & Equipment business sector, and Healthcare Facilities & Services industry with 92% confidence.

The company's capital structure shows no dilution risk, with basic and diluted shares outstanding being equal at 12,571,973 shares. However, liquidity risk could not be assessed due to missing balance-sheet inputs and absence of going-concern language in source documents. No valuation snapshot data is available to evaluate profitability or returns relative to industry benchmarks. The company's revenue concentration and geographic exposure are not disclosed in available documents, preventing assessment of segment or regional risk. No financial history or outlook data is available to determine growth trajectory or revenue trends. Risk assessment indicates low dilution potential, but liquidity risk remains unassessed due to missing financial data. No recent filings or transcripts are available to identify material events or strategic developments.
Key takeaways
  • The company shows no current dilution risk with equal basic and diluted share counts
  • Liquidity risk assessment is incomplete due to missing balance-sheet data
  • No valuation metrics are available for comparison to industry benchmarks
  • Revenue concentration and geographic exposure remain undisclosed
  • No recent financial or strategic developments are documented in available sources
  • # RATIONALES
  • {
  • "margin_outlook_rationale": "Unable to assess margin outlook due to lack of financial data",
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4
FY-3
FY-2
FY-1
FY0$83.7M$28.8M$20.4M-$20.3M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4
FY-3
FY-2
FY-1
FY0$158.9M$97.3M
PeriodOCFCapExFCFSBC
FY-4
FY-3
FY-2
FY-1
FY0$55.6M-$50.6M-$20.3M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricINVAActivity
Op margin7.7% medp25 -2.4% · p75 15.5%
Net margin5.9% medp25 -3.8% · p75 12.8%
Gross margin45.5% medp25 31.1% · p75 62.9%
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-7.0% medp25 -14.9% · p75 -3.2%
Debt / equity25.0% medp25 3.8% · p75 63.3%
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-05 01:39 UTC#2154cc28
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 05:40 UTCJob: f784023d